Published

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience applied
Date: 2025-01-01
Source: PubMed
DOI: 10.1016/j.nsa.2025.105525
PubMed: 40800003

Authors

Liechti ME Gasser P Aicher HD Mueller F Hawrot T Schmid Y

Watch author

Derived topics and classifications

psilocybin General Other

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial2026-05-27 Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.2025-01-01

Related papers

A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.The International journal on drug policy · 2026-08-01 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 Balancing safety and access in Oregon’s psilocybin servicesInternational Journal of Drug Policy · 2026-09-01 Defining 'psychedelic'.Journal of psychopharmacology (Oxford, England) · 2026-08-17 Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03 The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and SettingInternational Journal For Multidisciplinary Research · 2026-07-31 Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-09-01